Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.
Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia, and Australia.
In 2025, revenue amounted to SEK 28 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm.
Annual and sustainability report 2025
Explore Sobi’s financial performance, strategic progress and key achievements over the past year. The report provides a comprehensive view of our operations and value creation for shareholders.
Sobi Capital Markets Day 2026
Sobi hosted a Capital Markets Day on 18 February 2026.
Loading...
Press releases
Upcoming events
Loading...